NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · APM · USD
Stock price, earnings
Quote as of Aug 5, 2026, 07:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aptorum Group Limited’s quoted price sits in the lower half of its reported 52-week range, 81.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aptorum Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Sep 30, 2023 | -$22.20+14.62% vs estimate | $768.43K-3.95% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$2.23+$0.06 (+2.93%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 62.08% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$0.52-$0.03 (-4.96%)
Rocket One Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.87% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$0.73-$0.04 (-4.82%)
Oxbridge Re Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 60.75% below the high.
$2.93-$0.03 (-1.01%)
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 71.91% below the high.
$0.38$0.00 (0.0%)
Avenue Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.8% below the high.
